HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Vernon Bernardino has reiterated a 'Buy' rating on Phio Pharma (NASDAQ:PHIO) and maintained a $6 price target.
August 16, 2023 | 10:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharma's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $6 price target.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, the 'Buy' rating and $6 price target from HC Wainwright & Co. suggest a positive outlook for Phio Pharma, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100